Headquartered in Santa Monica, CA, Advanced Cell Technology, Inc. is a biotechnology company that develops cellular therapies for the treatment of both rare and common diseases. Using stem cell-based technologies and other proprietary methods in the field of regenerative medicine, ACTC aims to bring patient-specific therapies from the lab to the bedside so that they can help the millions of people affected by disease every day.
The company has three cellular product platforms based on ground breaking stem cell technology: Retinal Pigment Ephithelial (RPE) therapy, Myoblast stem cell therapy and the Hemangioblast (HG) platform. The company is in the process of commercializing its RPE for degenerative retinal disease and has secured two FDA clearances for Phase I/II clinical trials. ACT’s Myoblast stem cell therapy is already Phase-II approved for the treatment of chronic heart failure, advanced cardiac disease, myocardial infarction, and ischemia. Finally, ACT’S Hemangioblast (HG) platform is being developed for the treatment of blood and cardiovascular diseases.
Overseeing ACT’s development is an experienced management team and a world-class scientific team helmed by Interim Chairman and CEO Gary Rabin and Chief Scientific Officer Robert Lanza, M.D., respectively. For more information on the company please visit ww.advancedcell.com.
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment